Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CRON 
Cronos Group Inc (CRON)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: CRON (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $2.09
1 Year Target Price $2.09
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.96% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 987.99M USD | Price to earnings Ratio 51.6 | 1Y Target Price 2.09 |
Price to earnings Ratio 51.6 | 1Y Target Price 2.09 | ||
Volume (30-day avg) 5 | Beta 1.64 | 52 Weeks Range 1.60 - 2.77 | Updated Date 09/11/2025 |
52 Weeks Range 1.60 - 2.77 | Updated Date 09/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 14.19% | Operating Margin (TTM) -13.62% |
Management Effectiveness
Return on Assets (TTM) -1.84% | Return on Equity (TTM) 1.88% |
Valuation
Trailing PE 51.6 | Forward PE - | Enterprise Value 141001728 | Price to Sales(TTM) 7.58 |
Enterprise Value 141001728 | Price to Sales(TTM) 7.58 | ||
Enterprise Value to Revenue 1.08 | Enterprise Value to EBITDA -1.42 | Shares Outstanding 382940000 | Shares Floating 202326132 |
Shares Outstanding 382940000 | Shares Floating 202326132 | ||
Percent Insiders 47.07 | Percent Institutions 14.69 |
Upturn AI SWOT
Cronos Group Inc
Company Overview
History and Background
Cronos Group Inc. was founded in 2012 and is headquartered in Toronto, Canada. Initially known as PharmaCan Capital, it focused on acquiring licensed cannabis producers. It has since evolved into a global cannabinoid company with a diverse portfolio of brands.
Core Business Areas
- Cultivation and Production: Involves growing and manufacturing cannabis products, including dried flower, oils, and concentrates.
- Research and Development: Focuses on developing novel cannabis products and technologies, including proprietary genetics and formulations.
- Branded Products: Sales and marketing of a portfolio of cannabis brands, including Spinach, PEACE NATURALS and Lord Jones.
Leadership and Structure
Mike Gorenstein serves as Chairman, President, and CEO. The organizational structure includes departments focused on cultivation, R&D, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- Spinach: A recreational cannabis brand offering dried flower, pre-rolls, and edibles. Market share data is not publicly disclosed. Competitors include Aurora Cannabis, Canopy Growth, and Organigram.
- PEACE NATURALS: A wellness-focused brand offering cannabis oils and tinctures. Market share data is not publicly disclosed. Competitors include Charlotte's Web and CV Sciences.
- Lord Jones: A hemp-derived CBD products brand. Cronos acquired this brand. Market share data is not publicly disclosed. Competitors include cbdMD and Papa & Barkley.
Market Dynamics
Industry Overview
The cannabis industry is rapidly evolving, with increasing legalization and acceptance globally. The market is characterized by intense competition, evolving regulations, and growing consumer demand.
Positioning
Cronos Group Inc. aims to be a global cannabinoid company focusing on innovation and branded products. Their competitive advantage includes R&D capabilities and partnerships.
Total Addressable Market (TAM)
The global cannabis market is projected to reach hundreds of billions USD by 2030s. Cronos is positioned to capture a share through product innovation and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities
- Strategic partnership with Altria Group
- Global presence
- Diverse product portfolio
Weaknesses
- Limited profitability
- High operating expenses
- Dependence on regulatory changes
- Volatile stock price
Opportunities
- Expansion into new markets
- Development of innovative products
- Further legalization of cannabis
- Increased consumer adoption
Threats
- Intense competition
- Stringent regulations
- Fluctuations in cannabis prices
- Black market activity
Competitors and Market Share
Key Competitors
- TLRY
- CGC
- ACB
Competitive Landscape
Cronos Group Inc faces strong competition from larger and more established players. The company differentiates itself through innovation and partnerships, but must overcome profitability and market share challenges.
Major Acquisitions
Lord Jones
- Year: 2019
- Acquisition Price (USD millions): 300
- Strategic Rationale: Entry into the U.S. hemp-derived CBD market.
Growth Trajectory and Initiatives
Historical Growth: Evaluate Cronos Group Inc's revenue growth, market share gains, and product expansion over the past years.
Future Projections: Provide revenue and earnings projections for the next 3-5 years based on analyst consensus estimates.
Recent Initiatives: Highlight recent product launches, partnerships, and acquisitions that are expected to drive future growth.
Summary
Cronos Group Inc. is a global cannabinoid company with a strategic partnership with Altria. The company is growing, but profitability remains a challenge. Successful execution of its growth strategy and effective management of regulatory risks are crucial for future success. They need to improve market share and focus on strong innovation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports (Yahoo Finance, etc.)
- Industry news and reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cronos Group Inc
Exchange NASDAQ | Headquaters Stayner, ON, Canada | ||
IPO Launch date 2016-07-12 | President, CEO & Chairman Mr. Michael Ryan Gorenstein J.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 459 | Website https://thecronosgroup.com |
Full time employees 459 | Website https://thecronosgroup.com | ||
Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brand names. The company is based in Stayner, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.